E

Enzymatica AB (publ)
STO:ENZY

Watchlist Manager
Enzymatica AB (publ)
STO:ENZY
Watchlist
Price: 3.03 SEK
Market Cap: 735.5m SEK

EV/EBITDA
Enterprise Value to EBITDA

-13
Current
-10.2
Median
12.8
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-13
=
Enterprise Value
669.6m SEK
/
EBITDA
-51.6m SEK
EBITDA Growth EV/EBITDA to Growth
SE
E
Enzymatica AB (publ)
STO:ENZY
Average EV/EBITDA: 434
Negative Multiple: -13
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.9
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
15.1
13%
1.2
CH
Roche Holding AG
SIX:ROG
9.8
5%
2
CH
Novartis AG
SIX:NOVN
10.6
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131.2
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.7
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
2%
3.8

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-13.4
2-Years Forward
EV/EBITDA
-13.7
3-Years Forward
EV/EBITDA
N/A